A $750 Pill And A Founder Who Doesn’t Know When To Stop Tweeting
A Twitter account in the hands of a hothead startup founder can be a dangerous thing. The New York Times ran a piece Sunday looking into why a 62-year-old pill saw its price skyrocket from $13.50 to nearly $750 after it was acquired by Turing Pharmaceuticals last month. The increase in the price of Daraprim, a drug that the Times reported “is the standard of care for treating a life-threatening parasitic infection,” will undoubtedly have a major impact on those struggling to keep up with high prescription drug costs. The article continued: Dr. Aberg of Mount Sinai said some hospitals will now find Daraprim too expensive to keep in stock, possibly resulting in treatment delays. She said that Mount Sinai was continuing to use the drug, but each use now required a special review. “This seems to be all profit-driven for somebody,” Dr. Aberg said, “and I just think it’s a very dangerous process.” It was apparent that the news regarding Daraprim ...


Comments
Post a Comment